Aug 16, 2011 einstein dvt, einstein ext and einstein pe are phase iii studies designed to evaluate the efficacy and safety of rivaroxaban in the treatment andor prevention of recurrent, symptomatic vte in patients with acute symptomatic deep vein thrombosis or pulmonary embolism. Oral rivaroxaban for symptomatic venous thromboembolism nejm. Rivaroxaban inhibits factorxa in the coagulation cascade. The rate of major bleeding was also lower in the rivaroxaban group, as compared to standard therapy hr 0. Pdf rivaroxaban for the treatment of symptomatic deepvein. Rivaroxaban and usual care had similar rates of recurrent.
Jun 06, 2019 in the einstein dvt and einstein pe studies, xarelto was demonstrated to be noninferior to enoxaparinvka for the primary composite endpoint of time to first occurrence of recurrent dvt or nonfatal or fatal pe einstein dvt hr 95% ci. Einsteinpe investigators, buller hr, prins mh, lensin aw. The einstein pe study was designed to compare efficacy and safety of fixeddose oral rivaroxaban therapy against standard heparin plus warfarin in the treatment of symptomatic pulmonary emboli. Pdf rivaroxaban for the treatment of pulmonary embolism. Rivaroxaban will be administered in a body weightadjusted 20 mgequivalent total daily dose regimen using immediate release filmcoated tablets with a dosage of 5, 10, 15, or 20 mg, or an oral suspension 1 mgml. Oral rivaroxaban for the treatment of symptomatic venous. Rivaroxaban is a direct factor xa inhibitor used for treatment and prevention of venous thromboembolism vte.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg. The objective of einstein pe was to determine whether a singledrug approach with oral rivaroxaban is at least as effective as noninferior to dualdrug therapy with enoxaparinvka and to compare the safety of these two approaches in the treatment of patients with confirmed acute symptomatic pe with or without symptomatic dvt. The oral administration of rivaroxaban 15 mg twice a day for the first 3 weeks, followed by 20 mg. Rivaroxaban for cancerassociated venous thromboembolism. Patientreported treatment satisfaction with oral rivaroxaban. Oral rivaroxaban for symptomatic venous thromboembolism. The new oral factor xa inhibitor rivaroxaban proved equivalent to standard care of lmwh plus vitamink antagonist for the treatment of acute pulmonary embolism in the einstein pe study reported today. Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism.
Rivaroxaban is a new oral anticoagulant indicated for the treatment of venous thromboembolic events vte including deep vein thrombosis dvt and pulmonary embolism pe. Rivaroxaban will reduce symptomatic recurrent venous thromboembolism. We conducted the japanese j einstein dvt and pe program to compare rivaroxaban with the japanese. Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults. Can i use rivaroxaban to treat a pulmonary embolism pe in a patient with active cancer. Oral rivaroxaban versus standard therapy for the treatment of.
Background rivaroxaban, an oral factor xa inhibitor, may provide a simple, fixeddose regimen for treating acute. Oral rivaroxaban for japanese patients with symptomatic. Rivaroxaban for the treatment of venous thromboembolism in. The einstein pe study was an openlabel, randomized, phase iii study trial registration number nct00439777 comparing oral rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg once daily thereafter with subcutaneous enoxaparin overlapping with and followed by a vka warfarin or acenocoumarol. The einstein pe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in. Reduceddosed rivaroxaban in the longterm prevention of.
This is a multicenter, randomized, openlabel, assessorblind, eventdriven, noninferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism pe with or without symptomatic deepvein thrombosis dvt einstein pe. Published in, einsteinpe randomized 4, patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka. Randomized, openlabel phase iii noninferiority study active treatment. Mar 24, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw. The einsteinpe study was a randomized, openlabel trial of the efficacy and safety of rivaroxaban as compared with standard therapy consisting of enoxaparin and a vitamin k antagonist in.
Rivaroxaban was noninferior to standard therapy in preventing recurrent venous thromboembolism postpe hr 1. Rivaroxaban was noninferior to standard therapy in preventing recurrent venous thromboembolism post pe hr 1. Published in, einstein pe randomized 4, patients with acute pe to rivaroxaban or standard therapy with enoxaparin and a vka. Applications that remain active, even if the product has been discontinued, undergo safetyrelated labeling changes. Owing to differences in targeted anticoagulant intensities in japan, japanese patients were not enrolled into the global studies.
The results show that replacing the effective, but cumbersome, combination of injectable and oral agents at initiation of anticoagulation with a single oral anticoagulant rivaroxaban, which does not need routine monitoringproduced efficacy and safety outcomes that were similar. As in einstein dvt, treatment satisfaction was a predefined outcome in the einstein pe study, and here we compare the burdens and benefits of rivaroxaban as an oral fixeddose regimen, versus dualdrug standard of care in patients with pe enrolled in the einstein pe study. The einstendvt trial demonstrated that rivaroxaban is noninferior to standard therapy i. Owing to the different anticoagulant regimens used in japan, japanese patients were not enrolled into the global einstein dvt and pe trials. Pdf rivaroxaban versus standard anticoagulation for. Longterm anticoagulation with rivaroxaban for preventing. The primary efficacy outcome occurred in 17 of 1107 patients 1. Bodyweightadjusted rivaroxaban for children with venous.
Oral, direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or. Rivaroxaban or aspirin for extended treatment of venous. Oral direct factor xa inhibitor rivaroxaban in patients with acute symptomatic pulmonary embolism the einstein pe study. Einstein dvt and einstein pe were randomized, openlabel studies that compared the efficacy and safety of rivaroxaban with standard therapy, consisting of enoxaparin and adjusteddose vka, in patients with acute, symptomatic dvt andor pe.
Funded by bayer healthcare and janssen pharmaceuticals. Each study was eventdriven and required a number of events to provide 90% power using a margin of 2. Randomized, phase 3, multicenter, openlabel, parallelgroup, activecontrolled, eventdriven, noninferiority studies einstein dvt and einstein pe with patients receiving xarelto at an initial dose of 15 mg twice daily with food for the first 3 weeks, followed by xarelto 20 mg once daily with food or enoxaparin 1 mgkg twice daily for at least 5 days. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily thereafter was shown to be an effective and safe alternative to standard. In the einstein dvt and einstein pe studies, xarelto was demonstrated to be noninferior to enoxaparinvka for the primary composite endpoint of time to first occurrence of recurrent dvt or nonfatal or fatal pe einstein dvt hr 95% ci. As a 35yearold mom with young children, i appreciated the convenience, since it doesnt require injections or weekly blood tests. In this large, international, phase iii clinical program in more than 8000 patients with acute symptomatic dvt andor pe, monotherapy with rivaroxaban was shown to be as effective as dualdrug therapy with enoxaparin overlapping with and followed by vka. Rivaroxaban for the treatment of deep vein thrombosis or. The international multicenter study enrolled 3,396 patients average age 59 years, 45 percent women, 77 percent white. Patients were eligible if they were of legal age and had objectively confirmed acute, symptomatic dvt andor pe. The einstein pe 32 study involved patients with acute symptomatic pe with or without dvt. Final appraisal determination rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism issue date. Oral rivaroxaban versus standard therapy for the treatment. Idarucizumab for dabigatran reversal, rivaroxaban for pe.
Einstein jr is the largest pediatric study ever conducted for the treatment of vte and shows that the efficacy and safety profile of rivaroxaban. Einsteinpulmonary embolism pe study american college of. Dec 16, 20 the einstein dvt and einstein pe studies evaluated rivaroxaban for the treatment of vte. Rivaroxaban for treating pulmonary embolism and preventing. Oral, direct factor xa inhibitor rivaroxaban in patients with acute symptomatic deep vein thrombosis or pulmonary embolism. Rivaroxaban and the einstein clinical trial programme. Recurrence of pulmonary embolism while on rivaroxaban. Apr 14, 2019 oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Jun 30, 2019 oral rivaroxaban for the treatment of symptomatic pulmonary embolism. Pe, an international, eventdriven, openlabel, assessorblind, noninferiority study. The treatment regimens that we confirmed in children with bodyweights of at least 20 kg and the revised treatment regimens that we predicted in those with bodyweights less than 20 kg will be evaluated in the einstein jr phase 3 trial in children with acute venous thromboembolism.
A fixeddose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and longterm treatment of pulmonary embolism and had a potentially improved benefitrisk profile. Have the einstein pe investigators reported what is probably the next important advance in the treatment of pe. Oral direct factor xa inhibitor rivaroxaban in patients. Rivaroxaban and the einstein clinical trial programme ncbi. Pdf the worldwide einstein dvt and einstein pe studies randomized 8282 patients with acute symptomatic. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice daily for 21 days. Rivaroxaban compared with standard anticoagulants for the. Rivaroxaban for the treatment of symptomatic deepvein thrombosis and pulmonary embolism in chinese patients. The approval of rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism and the extended secondary prevention of recurrent vte is based on the results of the einstein dvt and einstein pe trials, and the einstein ext and einstein choice trials. Rivaroxaban for the treatment of deep vein thrombosis or pulmonary embolism.
Treatment with bodyweightadjusted rivaroxaban appears to be safe in children. Two studies, einstein dvt and einstein pe, compared a singledrug approach using the oral, direct factor xa inhibitor rivaroxaban with standardtherapy consisting of enoxaparin overlapping with and followed by a vka for the treatment of dvt andor pe 8, 9. Indeed, the einstein pe showed that a singledrug regimen of rivaroxaban start. The new oral factor xa inhibitor rivaroxaban proved equivalent to standard care of lmwh plus vitamink antagonist for the treatment of acute pulmonary embolism in the einstein. A prespecified pooled analysis of the einstein dvt and einstein pe studies compared the efficacy and safety of rivaroxaban 15 mg twicedaily for 21 days, followed by 20 mg oncedaily with standardtherapy enoxaparin 1.
The einstein dvt and einstein pe studies were each designed to test the hypothesis that rivaroxaban would be noninferior to standardtherapy. It is the largestever study of pe, recruiting and was significant 4 833 patients from 36 countries, including south africa. The einstein jr phase iii study 39 is a randomized, openlabel, study comparing the efficacy and safety of rivaroxaban 20mgequivalent dose regimens with those of standard anticoagulation for. Patientreported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Oral rivaroxaban for pulmonary embolism article pdf available in new england journal of medicine 36626. Treatment of venous thromboembolism open access journals.
In chinese patients with acute symptomatic dvt andor pe, rivaroxaban was as efficacious as enoxaparin. Rivaroxaban equals standard therapy, halves major bleeding. Pdf rivaroxaban and the einstein clinical trial programme. In the 2 pivotal clinical trials, where oral rivaroxaban was evaluated for the treatment of vte einstein and einsteinpe trials, 9,10 the results were consistent with all doac trials for the vte treatment when compared to heparin followed by vkasame efficacy profile with significantly lower bleeding rates was observed in noncancer patients. I developed a pulmonary embolism following a partial hysterectomy. Rivaroxaban versus standard anticoagulation for acute. Einstein choice is the first study to directly compare lowdose rivaroxaban and aspirin in this population in whom there is equipoise regarding the benefit of continued therapy. In the einstein pe study 3 of 4832 patients with acute symptomatic pulmonary embolism pe with or without deep vein thrombosis, it was demonstrated that rivaroxaban xarelto, bayer is at least as effective as the standard therapy of subcutaneous injections of the low molecular weight heparin lmwh enoxaparin and warfarin. Idarucizumab for dabigatran reversal, rivaroxaban for. Einstein extension trial, which compared continued rivaroxaban with placebo in 1,197 patients with symptomatic dvt or pe who had completed 6 to 12 months of anti coagulation and in whom physicians had equipoise with respect to the need for continued.
In a randomized, openlabel, eventdriven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deepvein thrombosis, we compared rivaroxaban. This was a predefined safety analysis of the einstein pe study, including pe patients, randomized to either enoxaparin with vitamin k antagonist vka or rivaroxaban. Background rivaroxaban, an oral factor xa inhibitor, may provide a simple, fixed dose regimen for treating acute. Among patients in the einstein choice trial who had completed a 6 to 12month course of anticoagulation for vte, extending anticoagulation with either prophylaxis 10 mg or treatment 20 mg doses of rivaroxaban for 1 year is superior to aspirin in reducing recurrent vte events. A prespecified pooled analysis of the einsteindvt and einsteinpe studies compared the efficacy and safety of rivaroxaban 15 mg. Rivaroxaban andor its metabolites were present in the milk of rats. The einstein dvt study investigated rivaroxaban compared with initial. In the einstein dvt and einstein pe trials, rivaroxaban 15 mg twice. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism. Oral direct factor xa inhibitor rivaroxaban in patients with.
Einstein pe investigators, buller hr, prins mh, lensin aw. In the einstein jr phase 1 and 2 studies, bodyweightadjusted rivaroxaban dose regimens with tablets or a newly developed oral suspension have been established for children aged between birth and 18 years matching the exposure range of young adults treated with rivaroxaban 20 mg once daily. Rivaroxaban for the treatment of venous thromboembolism in r. Rivaroxaban revolutionises treatment of pulmonary embolism. Rivaroxaban for the treatment of symptomatic deepvein. Anticoagulation using a fixeddose regimen of rivaroxaban has been shown to be as effective as standard anticoagulant therapy and is an attractive alternative due to its efficacy and lack of requirement of monitoring. Sep 05, 2019 einsteinpe investigators, buller hr, prins mh, lensin aw.
1355 1326 1166 580 321 399 548 911 380 474 1296 1519 780 399 1081 1396 622 1199 903 450 739 1523 834 230 418 605 945 1123 1132 366 491 893 626 845 930 1248 1156 803 1287 314 552 92 323 301 234 484